Long QT syndrome: importance of reassessing arrhythmic risk after treatment initiation
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Regularly reassessing risk scores for long QT syndrome (LQTS) and optimizing therapy, including beta-blockers, can reduce implantable cardioverter-defibrillator (ICD) implants without increasing life-threatening events.
Area Of Science
- Cardiology
- Genetics
- Pharmacology
Background
- Genetic arrhythmias, such as long QT syndrome (LQTS), require risk stratification.
- The M-FACT score was previously developed to assess risk in LQTS patients.
- This study evaluates the clinical utility of the M-FACT score in guiding patient management.
Purpose Of The Study
- To determine if adherence to M-FACT score recommendations is appropriate for managing LQTS patients.
- To assess the impact of risk score reassessment and therapy optimization on clinical outcomes.
- To evaluate the rate of implantable cardioverter-defibrillator (ICD) implantation and associated events.
Main Methods
- Included LQT1/2/3 and genotype-negative patients with specific clinical criteria.
- Focused on patients with an M-FACT score ≥2 (intermediate/high risk), both static and dynamic.
- Monitored clinical events, QTc intervals, and therapeutic interventions during follow-up.
Main Results
- Beta-blocker therapy in 94% of patients reduced QTc prolongation.
- During follow-up, no deaths occurred, with a low rate of cardiac events (4%) and aborted cardiac arrests (0.4%).
- Therapeutic optimization in patients with persistent high M-FACT scores led to a low incidence of cardiac events and reduced ICD implantation rates.
Conclusions
- Beta-blocker therapy can modify risk scores by shortening QTc intervals.
- Yearly risk reassessment and therapy optimization are crucial for appropriate management of LQTS.
- This approach allows for fewer ICD implants without compromising patient safety regarding life-threatening events.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
Related Concept Videos
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Arrhythmia or dysrhythmia refers to an abnormal heart rhythm caused by a defect in the heart's conduction system. It can cause the heart to beat irregularly, too quickly, or too slowly, leading to symptoms like chest pain, shortness of breath, and fainting. Factors such as stress, caffeine, alcohol, nicotine, cocaine, certain drugs, congenital defects, diseases, and electrolyte abnormalities can trigger arrhythmias.
Arrhythmias are categorized by their speed, rhythm, and origin. A slow...
Arrhythmias are irregular heart rhythms occurring when the heart's electrical impulses become abnormal. These disturbances can lead to various symptoms, depending on their severity and the underlying cause. Some common factors contributing to arrhythmias include hypoxia, ischemia, electrolyte imbalances, excessive catecholamine exposure, drug toxicity, and muscle overstretching. Arrhythmias can be classified into two main types based on the rate and site of origin of abnormal heart rhythms.
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
Arrhythmias are disturbances in the heart's rhythm that lead to abnormal heartbeats. These irregularities can originate from different parts of the heart and are classified based on their origin and nature.
Types of Arrhythmias
Sinus Node Arrhythmias
Sinus Bradycardia: Originating from the sinoatrial (SA) node, sinus bradycardia involves slower impulses, resulting in a heart rate of less than 60 beats per minute (bpm). Causes include sleep, vagal stimulation, beta-blockers, hypothyroidism,...